Natera, Inc. NTRA
We take great care to ensure that the data presented and summarized in this overview for Natera, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NTRA
View all-
Vanguard Group Inc Valley Forge, PA11.3MShares$1.41 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY6.77MShares$845 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY6.07MShares$757 Million0.06% of portfolio
-
Fred Alger Management, LLC New York, NY5.26MShares$656 Million2.83% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.46MShares$556 Million2.34% of portfolio
-
State Street Corp Boston, MA3.57MShares$446 Million0.02% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.31MShares$413 Million0.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.05MShares$380 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA2.61MShares$325 Million0.06% of portfolio
-
Rtw Investments, LP New York, NY2.59MShares$323 Million4.69% of portfolio
Latest Institutional Activity in NTRA
Top Purchases
Top Sells
About NTRA
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Insider Transactions at NTRA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 25
2024
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
124
+0.78%
|
-
|
Oct 25
2024
|
Roelof Botha |
BUY
Grant, award, or other acquisition
|
Direct |
203
+5.11%
|
-
|
Oct 25
2024
|
James Healy |
BUY
Grant, award, or other acquisition
|
Direct |
153
+0.33%
|
-
|
Oct 25
2024
|
Herm Rosenman |
BUY
Grant, award, or other acquisition
|
Direct |
178
+0.27%
|
-
|
Oct 25
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
691
-0.94%
|
$81,538
$118.81 P/Share
|
Oct 24
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
914
-1.23%
|
$108,766
$119.19 P/Share
|
Oct 23
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
496
-0.66%
|
$59,024
$119.09 P/Share
|
Oct 22
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.64%
|
-
|
Oct 22
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
199
-0.17%
|
$23,880
$120.07 P/Share
|
Oct 22
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
256
-0.23%
|
$30,720
$120.07 P/Share
|
Oct 22
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
454
-0.61%
|
$54,480
$120.07 P/Share
|
Oct 22
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
893
-0.46%
|
$107,160
$120.07 P/Share
|
Oct 22
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
349
-0.17%
|
$41,880
$120.07 P/Share
|
Oct 21
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
342
-0.3%
|
$41,040
$120.76 P/Share
|
Oct 21
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
294
-0.26%
|
$35,280
$120.76 P/Share
|
Oct 21
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
608
-0.81%
|
$72,960
$120.76 P/Share
|
Oct 21
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,145
+1.51%
|
-
|
Oct 21
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
1,709
-0.87%
|
$205,080
$120.76 P/Share
|
Oct 21
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
1,775
+0.9%
|
-
|
Oct 21
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
467
-0.22%
|
$56,040
$120.76 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 353K shares |
---|---|
Exercise of conversion of derivative security | 1.21M shares |
Bona fide gift | 361K shares |
Open market or private sale | 1.64M shares |
---|---|
Bona fide gift | 373K shares |